InsiderSignal.AI

InsiderSignal.ai

ADMA - Adma Biologics, Inc.

Insider Purchase by Elms Steve (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Elms Steve, serving as Dir at Adma Biologics, Inc. (ADMA), purchased 14,000 shares at $15.53 per share, for a total transaction value of $217,420.00. Following this transaction, Elms Steve now holds 2,143,750 shares of ADMA.

This purchase represents a 1.00% increase in Elms Steve's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, March 5, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 9, 2026, 4 days after the trade was made.

Adma Biologics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Elms Steve

Dir

Steven A. Elms is the Chairman of the Board of Directors at ADMA Biologics, Inc. (ADMA), a position he has held since joining the board in 2007. He also serves on the company's Governance and Nominations Committee.[[1]](https://www.admabiologics.com/about/board-of-directors)[[2]](https://fintool.com/app/research/companies/MRKR/people/steven-elms)[[5]](https://fintool.com/app/research/companies/ADMA/people/steven-a-elms) As a Managing Partner at Aisling Capital since 2000, Elms brings extensive expertise in life sciences investments.[[1]](https://www.admabiologics.com/about/board-of-directors)[[2]](https://fintool.com/app/research/companies/MRKR/people/steven-elms)[[3]](https://www.biospace.com/marker-therapeutics-appoints-steve-elms-to-its-board-of-directors) Elms has a distinguished career in investment banking and healthcare. Previously, he was a Principal in the Life Sciences Investment Banking Group at Hambrecht & Quist (later Chase H&Q), where he participated in over 60 financing and M&A transactions, raising more than $3.3 billion in capital. Earlier roles include trading mortgage-backed securities at Donaldson, Lufkin & Jenrette, pharmaceutical sales at Marion Laboratories, and consulting at The Wilkerson Group.[[1]](https://www.admabiologics.com/about/board-of-directors)[[3]](https://www.biospace.com/marker-therapeutics-appoints-steve-elms-to-its-board-of-directors) He currently serves on the boards of Elevation Oncology (Nasdaq: ELEV), Marker Therapeutics (Nasdaq: MRKR), and Treeline Biosciences, with past roles at Zosano Pharma and LOXO Oncology.[[1]](https://www.admabiologics.com/about/board-of-directors)[[2]](https://fintool.com/app/research/companies/MRKR/people/steven-elms) Elms holds a B.A. in Human Biology from Stanford University and an M.B.A. from Northwestern University's Kellogg Graduate School of Management.[[1]](https://www.admabiologics.com/about/board-of-directors)[[2]](https://fintool.com/app/research/companies/MRKR/people/steven-elms)[[3]](https://www.biospace.com/marker-therapeutics-appoints-steve-elms-to-its-board-of-directors)

View full insider profile →

Trade Price

$15.53

Quantity

14,000

Total Value

$217,420.00

Shares Owned

2,143,750

Trade Date

Thursday, March 5, 2026

11 days ago

SEC Filing Date

Monday, March 9, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Adma Biologics, Inc.

Company Overview

No company information available
View news mentioning ADMA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4629651

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime